The positive feedback loop between MET and VEGF/VEGFR2 may serve as a potential molecular marker for combination therapy in advanced NSCLC patients after resistance develops, and combined inhibition of MET and VEGF signaling pathways may further enhance the efficacy of the corresponding TKIs and overcome resistance. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.